1. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific

2. Agenda

3. Agenda

4. Control of BG by Insulin and Glucagon at the Individual Level

5. Increased HGP and Reduced Postprandial Glucagon Suppression in T2DM

6. Agenda

7. Basal Insulin Treatment Is Essential to Decreasing the FBG Level Continuously and Thoroughly

8. Basal Insulin Treatment Is Essential to Decreasing the FBG Level Continuously and Thoroughly (cont)

9. FBG Improvement Results in Better PPG Control

10. FBG Improvement Results in Better PPG Control (cont)

11. Basal Insulin Treatment in T2DM

12. Agenda

13. ADA/EASD Position Statement: A Patient-Centered Approach

14. Intensification Options for Patients With T2DM Uncontrolled on Basal Insulin

15. Premix vs Novel Co-formulated Short- Plus Long-Acting Insulin Analogue Combination

16. Simplification of Insulin Intensification

17. Adding a Short-Acting Insulin at Mealtime

18. IDegAsp Once Daily vs IGlar Once Daily in Patients With T2DM

19. Complementary Effects of Basal Insulin and GLP-1 RA Therapy

20. BIAsp 30 Premix vs IDegAsp Twice Daily

21. Quantity of Insulin: BIAsp 30 Premix vs IDegAsp

22. Patient-Centered Insulin Intensification

23. 1) 73-Year-Old Woman With T2DM: Insulin Antibody Positive

24. 90-Year-Old Man With T2DM

25. Simplified Therapy With Coformulated IDegAsp: 78-Year-Old Man With T2DM

27. IDeg During Hemodialysis

28. Hemodialysis/CAPD Patient Cases

29. Hemodialysis Case: Switch From Regular Insulin to IDegAsp

30. Patient and Physician Perspectives

31. Conclusions

32. Abbreviations

33. Abbreviations (cont)

34. Abbreviations (cont)